Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Operating revenue increased to JPY2.4bn (+58.4% YoY), with a net loss of JPY340mn, driven by rising R&D expenses.</li><li>Royalty income from four products and tegoprazan expansion reached JPY1.5bn, with milestone payments contributing to revenue.</li><li>Operating expenses totaled JPY2.4bn (+49.5% YoY), including significant R&D costs, leading to an operating loss of JPY27mn.</li></ul>

Operating revenue increased to JPY2.4bn (+58.4% YoY), with a net loss of JPY340mn, driven by rising R&D expenses.Royalty income from four products and tegoprazan expansion reached JPY1.5bn, with milestone payments contributing to revenue.Operating expenses totaled JPY2.4bn (+49.5% YoY), including significant R&D costs, leading to an operating loss of JPY27mn.

Raqualia Pharma (4579 JP): Q3 FY12/24 flash update